Overview

A Phase II Study of M2951 in SLE

Status:
Terminated

Trial end date:
2020-03-23

Target enrollment:

Participant gender:

Summary

M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study was to assess the Safety and Efficacy of M2951 in participants with Systemic Lupus Erythematosus (SLE).

Phase:

Phase 2

Details

Lead Sponsor:

EMD Serono Research & Development Institute, Inc.

Collaborators:

Merck KGaA
Merck KGaA, Darmstadt, Germany